Two types of primary mucinous ovarian tumors can be distinguished based on their origin

Michiel Simons, Femke Simmer, Johan Bulten, Marjolijn J. Ligtenberg, Harry Hollema, Shannon van Vliet, Richarda M. de Voer, Eveline J. Kamping, Dirk F. van Essen, Bauke Ylstra, Lauren E. Schwartz, Yihong Wang, Leon F. Massuger, Iris D. Nagtegaal, Robert J. Kurman

Research output: Contribution to journalArticle

Abstract

The origin of primary mucinous ovarian tumors is unknown. We explore the hypothesis that they originate from either Brenner tumors or teratomas and examine differences between the tumors that arise in these settings. A total of 104 Brenner tumor-associated mucinous tumors and 58 teratoma-associated mucinous tumors were analyzed. Immunohistochemistry for 21 antigens and fluorescence in situ hybridization for ERBB2 and MYC were performed. Genome-wide copy number analysis and mutation analysis for 56 cancer-related genes was carried out on a subset of mucinous ovarian tumors and their complementary Brenner tumor or teratoma. Patients with teratoma-associated mucinous tumors were significantly younger than patients with Brenner tumor-associated mucinous tumors (43 vs. 61 years). During progression from cystadenoma to atypical proliferative mucinous (borderline) tumor to carcinoma expression of typical gastrointestinal markers was increased in both Brenner tumor-associated and teratoma-associated mucinous tumors. Brenner tumor-associated mucinous tumors showed more frequently calcifications and Walthard cell nests, rarely expressed SATB2 and showed more often co-deletion of CDKN2A and MTAP. Teratoma-associated mucinous tumors were characterized by mucinous stromal dissection, SATB2 expression and RNF43 mutations. Other frequent mutations in both Brenner tumor-associated and teratoma-associated mucinous tumors were TP53 and KRAS mutations. Based on identical mutations or copy number profiles clonal relationships were indicated in two mucinous tumors and their associated Brenner tumor. Teratomas and Brenner tumors give rise to different subtypes of mucinous ovarian tumors. Subsequent progression pathways are comparable since both Brenner tumor-associated and teratoma-associated mucinous tumors develop a gastrointestinal immunophenotype during progression and show early mutations in KRAS and TP53. Teratoma-associated mucinous tumors may more closely resemble true gastrointestinal tumors, indicated by their expression of SATB2 and the presence of RNF43 mutations.

Original languageEnglish (US)
JournalModern Pathology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Brenner Tumor
Teratoma
Neoplasms
Mutation
Cystadenoma
Neoplasm Genes
Fluorescence In Situ Hybridization
Dissection

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Two types of primary mucinous ovarian tumors can be distinguished based on their origin. / Simons, Michiel; Simmer, Femke; Bulten, Johan; Ligtenberg, Marjolijn J.; Hollema, Harry; van Vliet, Shannon; de Voer, Richarda M.; Kamping, Eveline J.; van Essen, Dirk F.; Ylstra, Bauke; Schwartz, Lauren E.; Wang, Yihong; Massuger, Leon F.; Nagtegaal, Iris D.; Kurman, Robert J.

In: Modern Pathology, 01.01.2019.

Research output: Contribution to journalArticle

Simons, M, Simmer, F, Bulten, J, Ligtenberg, MJ, Hollema, H, van Vliet, S, de Voer, RM, Kamping, EJ, van Essen, DF, Ylstra, B, Schwartz, LE, Wang, Y, Massuger, LF, Nagtegaal, ID & Kurman, RJ 2019, 'Two types of primary mucinous ovarian tumors can be distinguished based on their origin', Modern Pathology. https://doi.org/10.1038/s41379-019-0401-y
Simons, Michiel ; Simmer, Femke ; Bulten, Johan ; Ligtenberg, Marjolijn J. ; Hollema, Harry ; van Vliet, Shannon ; de Voer, Richarda M. ; Kamping, Eveline J. ; van Essen, Dirk F. ; Ylstra, Bauke ; Schwartz, Lauren E. ; Wang, Yihong ; Massuger, Leon F. ; Nagtegaal, Iris D. ; Kurman, Robert J. / Two types of primary mucinous ovarian tumors can be distinguished based on their origin. In: Modern Pathology. 2019.
@article{d4c9d72c70e64c9188603b36156d01bb,
title = "Two types of primary mucinous ovarian tumors can be distinguished based on their origin",
abstract = "The origin of primary mucinous ovarian tumors is unknown. We explore the hypothesis that they originate from either Brenner tumors or teratomas and examine differences between the tumors that arise in these settings. A total of 104 Brenner tumor-associated mucinous tumors and 58 teratoma-associated mucinous tumors were analyzed. Immunohistochemistry for 21 antigens and fluorescence in situ hybridization for ERBB2 and MYC were performed. Genome-wide copy number analysis and mutation analysis for 56 cancer-related genes was carried out on a subset of mucinous ovarian tumors and their complementary Brenner tumor or teratoma. Patients with teratoma-associated mucinous tumors were significantly younger than patients with Brenner tumor-associated mucinous tumors (43 vs. 61 years). During progression from cystadenoma to atypical proliferative mucinous (borderline) tumor to carcinoma expression of typical gastrointestinal markers was increased in both Brenner tumor-associated and teratoma-associated mucinous tumors. Brenner tumor-associated mucinous tumors showed more frequently calcifications and Walthard cell nests, rarely expressed SATB2 and showed more often co-deletion of CDKN2A and MTAP. Teratoma-associated mucinous tumors were characterized by mucinous stromal dissection, SATB2 expression and RNF43 mutations. Other frequent mutations in both Brenner tumor-associated and teratoma-associated mucinous tumors were TP53 and KRAS mutations. Based on identical mutations or copy number profiles clonal relationships were indicated in two mucinous tumors and their associated Brenner tumor. Teratomas and Brenner tumors give rise to different subtypes of mucinous ovarian tumors. Subsequent progression pathways are comparable since both Brenner tumor-associated and teratoma-associated mucinous tumors develop a gastrointestinal immunophenotype during progression and show early mutations in KRAS and TP53. Teratoma-associated mucinous tumors may more closely resemble true gastrointestinal tumors, indicated by their expression of SATB2 and the presence of RNF43 mutations.",
author = "Michiel Simons and Femke Simmer and Johan Bulten and Ligtenberg, {Marjolijn J.} and Harry Hollema and {van Vliet}, Shannon and {de Voer}, {Richarda M.} and Kamping, {Eveline J.} and {van Essen}, {Dirk F.} and Bauke Ylstra and Schwartz, {Lauren E.} and Yihong Wang and Massuger, {Leon F.} and Nagtegaal, {Iris D.} and Kurman, {Robert J.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41379-019-0401-y",
language = "English (US)",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Two types of primary mucinous ovarian tumors can be distinguished based on their origin

AU - Simons, Michiel

AU - Simmer, Femke

AU - Bulten, Johan

AU - Ligtenberg, Marjolijn J.

AU - Hollema, Harry

AU - van Vliet, Shannon

AU - de Voer, Richarda M.

AU - Kamping, Eveline J.

AU - van Essen, Dirk F.

AU - Ylstra, Bauke

AU - Schwartz, Lauren E.

AU - Wang, Yihong

AU - Massuger, Leon F.

AU - Nagtegaal, Iris D.

AU - Kurman, Robert J.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The origin of primary mucinous ovarian tumors is unknown. We explore the hypothesis that they originate from either Brenner tumors or teratomas and examine differences between the tumors that arise in these settings. A total of 104 Brenner tumor-associated mucinous tumors and 58 teratoma-associated mucinous tumors were analyzed. Immunohistochemistry for 21 antigens and fluorescence in situ hybridization for ERBB2 and MYC were performed. Genome-wide copy number analysis and mutation analysis for 56 cancer-related genes was carried out on a subset of mucinous ovarian tumors and their complementary Brenner tumor or teratoma. Patients with teratoma-associated mucinous tumors were significantly younger than patients with Brenner tumor-associated mucinous tumors (43 vs. 61 years). During progression from cystadenoma to atypical proliferative mucinous (borderline) tumor to carcinoma expression of typical gastrointestinal markers was increased in both Brenner tumor-associated and teratoma-associated mucinous tumors. Brenner tumor-associated mucinous tumors showed more frequently calcifications and Walthard cell nests, rarely expressed SATB2 and showed more often co-deletion of CDKN2A and MTAP. Teratoma-associated mucinous tumors were characterized by mucinous stromal dissection, SATB2 expression and RNF43 mutations. Other frequent mutations in both Brenner tumor-associated and teratoma-associated mucinous tumors were TP53 and KRAS mutations. Based on identical mutations or copy number profiles clonal relationships were indicated in two mucinous tumors and their associated Brenner tumor. Teratomas and Brenner tumors give rise to different subtypes of mucinous ovarian tumors. Subsequent progression pathways are comparable since both Brenner tumor-associated and teratoma-associated mucinous tumors develop a gastrointestinal immunophenotype during progression and show early mutations in KRAS and TP53. Teratoma-associated mucinous tumors may more closely resemble true gastrointestinal tumors, indicated by their expression of SATB2 and the presence of RNF43 mutations.

AB - The origin of primary mucinous ovarian tumors is unknown. We explore the hypothesis that they originate from either Brenner tumors or teratomas and examine differences between the tumors that arise in these settings. A total of 104 Brenner tumor-associated mucinous tumors and 58 teratoma-associated mucinous tumors were analyzed. Immunohistochemistry for 21 antigens and fluorescence in situ hybridization for ERBB2 and MYC were performed. Genome-wide copy number analysis and mutation analysis for 56 cancer-related genes was carried out on a subset of mucinous ovarian tumors and their complementary Brenner tumor or teratoma. Patients with teratoma-associated mucinous tumors were significantly younger than patients with Brenner tumor-associated mucinous tumors (43 vs. 61 years). During progression from cystadenoma to atypical proliferative mucinous (borderline) tumor to carcinoma expression of typical gastrointestinal markers was increased in both Brenner tumor-associated and teratoma-associated mucinous tumors. Brenner tumor-associated mucinous tumors showed more frequently calcifications and Walthard cell nests, rarely expressed SATB2 and showed more often co-deletion of CDKN2A and MTAP. Teratoma-associated mucinous tumors were characterized by mucinous stromal dissection, SATB2 expression and RNF43 mutations. Other frequent mutations in both Brenner tumor-associated and teratoma-associated mucinous tumors were TP53 and KRAS mutations. Based on identical mutations or copy number profiles clonal relationships were indicated in two mucinous tumors and their associated Brenner tumor. Teratomas and Brenner tumors give rise to different subtypes of mucinous ovarian tumors. Subsequent progression pathways are comparable since both Brenner tumor-associated and teratoma-associated mucinous tumors develop a gastrointestinal immunophenotype during progression and show early mutations in KRAS and TP53. Teratoma-associated mucinous tumors may more closely resemble true gastrointestinal tumors, indicated by their expression of SATB2 and the presence of RNF43 mutations.

UR - http://www.scopus.com/inward/record.url?scp=85074839524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074839524&partnerID=8YFLogxK

U2 - 10.1038/s41379-019-0401-y

DO - 10.1038/s41379-019-0401-y

M3 - Article

C2 - 31695154

AN - SCOPUS:85074839524

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

ER -